ResMed Inc. (RMD)
The IRS Makes You Sell Whether the Market Is Up or Down. These 3 ETFs Fund the RMD Without Touching a Share
Turning 73 changes the math on your retirement account. The IRS no longer lets your traditional IRA compound in peace.
ResMed Q4 Earnings Call Highlights
ResMed NYSE: RMD reported fourth-quarter fiscal 2026 revenue growth of 9% on a reported basis, or 8% in constant currency, as demand for sleep devices and masks increased. Non-GAAP earnings per share rose 16% to $2.95, while the company expanded gross margin despite continued inflation in electronic components and freight.
RMD Stock Down Despite Q4 Earnings Beat, Revenues Rise Y/Y
Resmed's Q4 earnings and revenues beat estimates, but shares fall as fiscal 2027 revenue guidance trails the consensus mark.
ResMed Inc. (RMD) Q4 2026 Earnings Call Transcript
ResMed Inc. (RMD) Q4 2026 Earnings Call Transcript
ResMed (RMD) Q4 Earnings and Revenues Top Estimates
ResMed (RMD) came out with quarterly earnings of $2.95 per share, beating the Zacks Consensus Estimate of $2.9 per share. This compares to earnings of $2.55 per share a year ago.
Curious about ResMed (RMD) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Evaluate the expected performance of ResMed (RMD) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Resmed's Q4 Earnings on Deck: What's in Store for the Stock?
RMD's Q4 results may reflect strong mask and device demand, portfolio innovation, acquisitions and digital health growth, with EPS seen rising 13.7%.
ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care
RMD's MatrixCare sale sharpens its focus on sleep, breathing and connected care while freeing resources for AI-powered digital health.
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ResMed to sell software business MatrixCare for $490 million
ResMed said on Tuesday it would sell its software business MatrixCare to private equity firm Frazier Healthcare Partners for $490 million in cash, as the health technology company sharpens its focus on sleep, breathing and home-based care.
